Citi raised the firm’s price target on Lenz Therapeutics (LENZ) to $49 from $45 and keeps a Buy rating on the shares post the Q2 report. The firm increased estimates to reflect the company’s South Korea and Canada licensing agreements.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LENZ:
- Lenz Therapeutics Prepares for LNZ100 Launch
- LENZ Therapeutics: Positioned for Growth with Strategic Global Expansion and Imminent FDA Approval
- Lenz Therapeutics reports Q2 EPS (53c), consensus (54c)
- Lenz announces CORXEL submitted NDA for LNZ100 in China
- Lenz Therapeutics price target raised to $48 from $38 at H.C. Wainwright